Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Olorofim in Hepatic Impairment
NCT04752540Phase 1Completed
- Sponsor
- F2G
- Start
- Jul 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olorofim in invasive fungal infection (IFI) (3 arms), sponsored by F2G. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration and Maximum Observed Plasma Concentration. Started Jul 2021; status: completed.
02
Drugs
olorofim
03
Conditions
invasive fungal infection (IFI)
Beyond the preview
Go deeper on NCT04752540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04752540.